Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Novel therapies for hepatitis C virus based on lessons from virology. Clinical gastroenterology and hepatology Glenn, J. S. 2005; 3 (10): S86-8

Abstract

As we improve our understanding of the molecular virology of hepatitis C virus (HCV), a variety of new potential antiviral strategies are emerging. Moving beyond interferon and ribavirin, these new strategies for the first time are aimed at HCV-specific targets. It is expected, by analogy with other infections, that effective pharmacologic control of HCV will be achieved best by using a cocktail of such virus-specific agents, each designed against an independent target. As a result, the way we treat HCV should change dramatically over the next few years.

View details for PubMedID 16234068